Satavaptan (sr121463)    (DrugBank: Satavaptan)

1 disease
IDDisease name (Link within this page)Number of trials
72Pituitary ADH secretion disorder1

72. Pituitary ADH secretion disorder    [ 36 clinical trials,   22 drugs,   (DrugBank: 5 drugs),   2 drug target genes,   4 drug target pathways]
Searched query = "Pituitary ADH secretion disorder", "Inappropriate antidiuretic hormone secretion", "Syndrome of inappropriate secretion of antidiuretic hormone", "Inappropriate ADH syndrome", "Syndrome of inappropriate ADH", "Central diabetes insipidus", "Syndrome of inappropriate secretion of ADH", "SIADH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 36 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00728091
(ClinicalTrials.gov)
July 200831/7/2008A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional HyponatremiaA Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)Hyponatremia;Inappropriate ADH SyndromeDrug: satavaptan (SR121463);Drug: placeboSanofiNULLTerminated18 YearsN/ABoth2Phase 3United States